A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine [pneumococcal 13-valent CRM197 vaccine conjugate] in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico.

Trial Profile

A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine [pneumococcal 13-valent CRM197 vaccine conjugate] in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2011

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 09 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top